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Abstract We recently reported the identification of human
calumenin, a novel Ca2+ binding, transformation-sensitive and
secreted protein [Vorum et al. (1998) Biochim. Biophys. Acta
1386, 121^131; Vorum et al. (1999) Exp. Cell Res. 248, 473^
481] belonging to the family of multiple EF-hand proteins of the
secretory pathway that include reticulocalbin, ERC-55, Cab45
and crocalbin. In order to further investigate the extracellular
functions of calumenin we immobilized the recombinant protein
to a column. After application of a placental tissue extract we
were able to elute one protein that interacts with calumenin in the
presence of Ca2+. Amino acid sequencing identified this protein
as serum amyloid P component (SAP). Furthermore, we verified
and characterized the calumenin-SAP interaction by the surface
plasmon resonance technique. The findings indicate that
calumenin may participate in the immunological defense system
and could be involved in the pathological process of amyloidosis
that leads to formation of amyloid deposits seen in different types
of tissues.
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1. Introduction
The endoplasmic reticulum (ER) harbors a number of pro-
teins responsible for binding and storage of Ca2, such as
calreticulin [1], endoplasmin [2], BiP/immunoglobulin heavy
chain-binding protein [3], PDI/protein disul¢de-isomerase [4]
and calnexin [5,6] which all coordinate the Ca2 ion in
stretches of highly acidic amino acids [7]. The function of
these proteins is thought to be storage for calreticulin [8]
whereas endoplasmin, BiP, PDI and calnexin belong to the
molecular chaperones involved in the folding and maturation
of newly synthesized proteins [9]. Recent reports show that,
besides the above mentioned proteins, the ER also harbors
proteins coordinating Ca2 to multiple EF-hand helix-loop-
helix motifs [10]. These include reticulocalbin [11], ERC-55
[12], calumenin [13,14] and crocalbin [15]. Much less is known
about the function of the latter family. So far, ERC-55 and
crocalbin have been reported to interact with other proteins.
ERC-55 interacts with the vitamin D receptor modulating its
function [16] and with the transforming protein, E6, from
papillomavirus [17]. Furthermore, ERC-55 and crocalbin in-
teract with the snake venom toxins taipoxin [18] and crotoxin
[19], respectively.
Among the EF-hand family members of the secretory path-
way we have recently found that calumenin is not restricted to
the ER but also found in the Golgi complex as well as being
secreted [20]. Furthermore, we have found that calumenin
binds Ca2 with a rather low a⁄nity around 1.6U103 M31
corresponding to a Kd around 0.6 mM for each of the EF-
hands [14]. However, this rather low a⁄nity may be ideal for
Ca2-regulated interactions under conditions of relatively high
Ca2 concentrations as present in the secretory pathway and
extracellularly, i.e. the locations where calumenin is found.
In the present report we have searched for Ca2-dependent
protein interactions with calumenin by immobilizing recombi-
nant calumenin to a column. After application of a placental
tissue extract and washing with a high concentration of salt
we were able to elute one protein that interacts with calum-
enin in the presence of Ca2. Sequencing of a tryptic internal
peptide identi¢ed this protein as serum amyloid P component
(SAP). The binding of calumenin to SAP was further veri¢ed
and characterized by the surface plasmon resonance techni-
que.
2. Materials and methods
2.1. Expression of recombinant calumenin in Escherichia coli
Expression of recombinant calumenin in E. coli and subsequent
chromatographic puri¢cation procedures were done as previously de-
scribed in detail [14].
2.2. A⁄nity puri¢cation and identi¢cation of a calumenin interacting
protein from human placenta
Placentas from normal human afterbirths were handled as described
[21]. In brief, pieces of villous tissue were washed in PBS, homogen-
ized at 0‡C in 0.25 M sucrose, 10 mM HEPES, 5 mM EDTA, 0.1 mM
PMSF, pH 7.4 and centrifuged at 600Ug for 3 min. After removal of
the supernatant, the pellet was homogenized and centrifuged at
600Ug. The supernatants were combined and centrifuged again at
3000Ug for 5 min. The new supernatant was then centrifuged at
48 000Ug for 40 min and the pellet homogenized in 140 mM NaCl,
0.6 mM CaCl2, 10 mM sodium phosphate, 0.1 mM PMSF, pH 7.8.
The proteins were solubilized in the same bu¡er with 0.5% CHAPS.
This suspension was stirred for 10 min at 0‡C and then centrifuged for
40 min at 48 000Ug.
The ¢nal supernatant was applied to a column of immobilized
recombinant calumenin [14] equilibrated in MB-bu¡er (2 mM CaCl2,
1 mM MgCl2, 140 mM NaCl, 10 mM HEPES, pH 7.4) and to a
control column equilibrated in MB-bu¡er without calumenin immo-
bilized. The columns were washed in MB-bu¡er with 1 M NaCl and
0.1% CHAPS and eluted with MB-bu¡er containing 10 mM EDTA
and 0.1% CHAPS. The eluate was analyzed for potential ligands by
gel electrophoresis.
Eluted proteins from several puri¢cations were pooled, upconcen-
trated, electrophoresed, Western blotted onto PVDF membranes and
amido black stained. Two protein bands were cut from the membrane
and internal sequenced after tryptic digestion at the Protein Structure
Core Facility, University of Nebraska Medical Center (Omaha, NE,
USA).
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After protein identi¢cation the column was also used to check its
ability to capture 75 Wg of pure SAP from a solution in MB-bu¡er.
Pure SAP was dissolved in MB-bu¡er applied to the calumenin col-
umn equilibrated in MB-bu¡er. The column was then washed in MB-
bu¡er with 1 M NaCl and 0.1% CHAPS and eluted with MB-bu¡er
containing 10 mM EDTA and 0.1% CHAPS.
2.3. Analyses of calumenin-SAP interaction by surface plasmon
resonance
Surface plasmon resonance measurements were performed on a
BIAcore 2000 instrument (Biacore, Uppsala, Sweden). This technol-
ogy relies on the phenomenon of the surface plasmon resonance that
occurs when surface plasmon waves are excited at a metal/liquid inter-
face. Light is directed at, and re£ected from, the side of the surface
not in contact with sample, and surface plasmon resonance causes a
reduction in the re£ected light intensity at a speci¢c combination of
angle and wavelength. Biomolecular binding events cause changes in
the refractive index at the surface layer, which are detected as changes
in the surface plasmon resonance signal. In general, the refractive
index change is proportional to change in mass concentration at the
surface layer.
Coupling of calumenin was performed by using the amine coupling
method [22]. A continuous £ow of HBS bu¡er (10 mM HEPES pH
7.4, 3.4 mM EDTA, 150 mM NaCl, 0.005% surfactant P20) passing
over the sensor surface of a CM5 sensor chip was maintained at 5 Wl
min31. The carboxylated dextran matrix of the sensor chip £ow cell
1 and 2 was activated by the injection of 60 Wl of a solution containing
0.2 M N-ethyl-NP-(3-dimethylaminopropyl)carbodiimide and 0.05 M
N-hydroxysuccimide in water. Calumenin was then at a concentration
of 175 Wg ml31 in 10 mM sodium formate pH 3.5, injected over £ow
cell 1 with a £ow rate of 5 Wl min31. Totally 60 Wl was injected. The
remaining binding sites in both £ow cells were blocked by injection of
35 Wl 1 M ethanolamine pH 8.5. The surface plasmon resonance signal
from immobilized calumenin generated 2431 BIAcore response units
(RU) equivalent to 66 fmol calumenin/mm2.
Commercially available SAP obtained from Calbiochem (Bad So-
den, Germany) was dissolved in 10 mM HEPES, 150 mM NaCl, 2 mM
CaCl2, 1 mM EGTA, pH 7.4 at a concentration of 50 nM and ana-
lyzed by injecting 40 Wl onto the derivatized sensor chip and the
control £ow channel. In order to further investigate the calumenin-
SAP interaction in a serum-like medium, human serum was fractio-
nated through serially arranged Superdex 75 and Superdex 200 col-
umns (Pharmacia). About 200 fractions each containing approxi-
mately 1 ml were analyzed for the presence of SAP and SAP
depleted fractions were analyzed by injecting 40 Wl onto the derivat-
ized sensor chip and the control £ow channel. The samples were
dissolved in 10 mM HEPES, 150 mM NaCl, 2 mM CaCl2, 1 mM
EGTA, pH 7.4. Running bu¡er consisted of 10 mM HEPES, 150 mM
NaCl, 1.5 mM CaCl2, 1 mM EGTA, pH 7.4. The BIAcore response is
expressed in relative RU, i.e. the di¡erence in response between £ow
cell with immobilized calumenin and the control £ow channel. Inject-
ing two times 10 Wl 1.6 M glycine-HCl bu¡er, pH 3.0, performed
regeneration of the sensor chip after each analysis cycle.
3. Results
3.1. Calumenin forms high molecular mass aggregates in
solution
The deduced molecular mass of calumenin is 37 kDa and it
migrates with an apparent molecular mass around 50 kDa in
Fig. 1. Gel ¢ltration of calumenin on a Superdex 200 column. A: A
chromatographic separation of K2-macroglobulin (720 kDa), IgG
(160 kDa), albumin (67 kDa), ovalbumin (43 kDa), and myoglobin
(17 kDa). B: A chromatographic elution of calumenin in 150 mM
NaCl, 20 mM HEPES, pH 7.4. C: A chromatographic elution of
calumenin in 8 M urea, 100 mM NaH2PO4, 10 mM Tris^HCl, pH
8.0, 100 mM DTT.
Fig. 2. A: Gel electrophoresis of calumenin a⁄nity-puri¢ed placenta
proteins. Silver stained gel of placenta proteins upconcentrated on a
column with immobilized calumenin (lane 1) and a reference column
without calumenin (lane 2) both eluted with MB-bu¡er containing
10 mM EDTA and 0.1% CHAPS. The bands termed a and c are
only present in the calumenin containing column. The c band was
identi¢ed by internal peptide sequencing as SAP. B: Gel electropho-
resis analysis of eluted fractions from a⁄nity chromatography of
pure SAP dissolved in MB-bu¡er. Upper part: silver staining and
lower part: Western blot reacted with anti-SAP. Lane 1: Pure SAP
in MB-bu¡er before application to column. Lane 2: Flow-through
in MB-bu¡er. Lane 3: Wash (MB-bu¡er with 1 M NaCl and 0.1%
CHAPS). Lane 4: Elution (MB-bu¡er containing 10 mM EDTA
and 0.1% CHAPS). The eluted fractions were upconcentrated to
similar volumes and comparable amounts were applied to each lane.
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SDS gels, apparently due to its acidic pI [14]. During the
puri¢cation procedure of the recombinant protein we noticed
that the protein in solution forms aggregates with much high-
er molecular mass than the monomer protein. Fig. 1 shows an
eluate from a gel chromatographic separation of the recombi-
nant protein on a Pharmacia Superdex 200 column. This col-
umn is suitable for separation of proteins with elution vol-
umes between 60 and 100 ml corresponding to molecular
masses in an approximate range between 17 and 720 kDa as
observed by the chromatographic separation of K2-macroglo-
bulin (720 kDa), IgG (160 kDa), albumin (67 kDa), ovalbu-
min (43 kDa) and myoglobin (17 kDa) (Fig. 1A). The elution
volume of calumenin is spread out between around 50 ml
tailing o¡ to around 80 ml corresponding to aggregates with
molecular masses from about 300 kDa to beyond that of K2-
macroglobulin at 720 kDa (Fig. 1B). Separate analyses by gel
electrophoresis of samples from the eluate showed that the
three peaks all contained the recombinant protein migrating
as expected in SDS gels around 50 kDa (Fig. 1B, inset). It is
obvious that the concentration of monomer protein at 37
kDa, with an elution volume around 90^95 ml, is negligible.
Thus evidently, calumenin forms higher molecular mass ag-
gregates in solution without denaturing agents present. When
urea was added to the elution bu¡er together with dithiothrei-
tol the protein peak could be isolated with an elution volume
that was in agreement with the molecular mass of the mono-
mer protein at 37 kDa (Fig. 1C).
3.2. A⁄nity puri¢cation of SAP by immobilized calumenin
The observation that calumenin is secreted as well as being
localized in the secretory pathway indicates that the protein
may have functions extracellularly as well as intracellularly. In
order to address this question we immobilized calumenin to a
column with the purpose of purifying putative interacting
proteins from a placental tissue extract. Proteins that were
captured by the immobilized calumenin in the presence of
Ca2 were eluted again with EDTA. Several liters of tissue
extract were a⁄nity puri¢ed on the column, gel electrophor-
esed, and blotted onto a PVDF membrane. After amido black
staining several bands could be detected. A representative
silver stained gel of the preparation is shown in Fig. 2A
(lane 1). A strong band migrating around 30 kDa was found
C
Fig. 3. Surface plasmon resonance analysis of the binding of calum-
enin to SAP. Calumenin was immobilized to a sensor chip, and the
on and o¡ rates for ligand binding were recorded on a BIAcore
2000. The arrows indicate start of injection of ligand (association
phase) or the start of injection of bu¡er alone (dissociation phase).
The recorded sensorgrams in (A) show binding of SAP to immobi-
lized calumenin in 10 mM HEPES, 150 mM NaCl, 2 mM CaCl2,
1 mM EGTA, pH 7.4 (curve 1). The interaction was veri¢ed by the
additional binding of anti-SAP antibody. Curve 2 is a control with
calumenin replaced with bu¡er showing no binding of anti-SAP to
calumenin. B: Western blots reacted with anti-SAP antibody of
fractions of a chromatographic separation of serum proteins. Frac-
tions #72^76 contain SAP whereas fractions #88^92 were devoid of
SAP. C: Binding of pooled SAP-enriched fractions (#72^76) to im-
mobilized calumenin in 10 mM HEPES, 150 mM NaCl, 2 mM
CaCl2, 1 mM EGTA, pH 7.4. Curves 1^7 show 1, 2, 3, 4, 5, 10 and
20U diluted fractions. Curve 8 shows absence of binding with the
addition of 3.4 mM EDTA. D: Veri¢cation of SAP binding to im-
mobilized calumenin by the additional binding of anti-SAP antibody
(curve 1). SAP dilution corresponds to curve 3 in Fig. 3C. Curve 2
is a control with anti-SAP antibody replaced with bu¡er. Curve 3 is
a control demonstrating that anti-SAP antibody does not react with
immobilized calumenin alone. E: Binding of pooled SAP-depleted
fractions (#88^92) with the addition of commercial SAP veri¢ed by
the addition of anti-SAP antibody (curve 1). Curve 2 is a control
with anti-SAP replaced with bu¡er. Curve 3 is a control showing
no binding of pooled SAP-depleted fractions without the addition
of commercial SAP.
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in the eluate from the column with immobilized calumenin
(marked b in lane 1) as well as from the reference column
without immobilized calumenin (lane 2). This interaction
was therefore considered to be artifactual. However, two oth-
er bands, one around 50 kDa (marked a in lane 1) and one
around 25 kDa (marked c in lane 1), were found in the eluate
from the calumenin column but not in the eluate from the
reference column (lane 2). Both of these bands were cut out
for internal peptide sequencing. Unfortunately, only the c
band was present in su⁄cient amounts giving the peptide
sequence; (Q)GYFVEAQPK which unequivocally identi¢ed
c as SAP.
The very low amounts of SAP puri¢ed from the extract
might indicate that the SAP calumenin interaction is of low
a⁄nity and that only small amounts of the SAP present were
puri¢ed. Therefore, we Western blotted a sample of the pla-
centa extract before application to the column. The blot was
exposed to anti-SAP and revealed that only a very small
amount was present in the sample (not shown). We then an-
alyzed the a⁄nity of calumenin for SAP by applying a pure
solution of SAP to the column (Fig. 2B, lane 1). Analysis of
the £ow-through fraction revealed that all the calumenin ap-
plied to the column was bound to it (Fig. 2B, lane 2). The
interaction was resistant to a wash in 1 M NaCl (Fig. 2B, lane
3) indicating that the interaction is strong and thereby puta-
tively of physiological signi¢cance. However, the strong inter-
action was inhibited and SAP could be eluded when EDTA
was applied to the column (Fig. 2B, lane 4).
3.3. Characterization of the calumenin-SAP interaction
The binding of calumenin to SAP was veri¢ed and charac-
terized by the surface plasmon resonance technique described
in detail in Section 2.3. Human recombinant calumenin was
immobilized to a sensor chip, and the on and o¡ rates for
SAP binding were recorded as seen in Fig. 3A,C,D,E. Arrows
indicate start of sample injection (association phase) or start
of injection of bu¡er alone (dissociation phase). In Fig. 3A
(curve 1) an increase in response was seen when the sensor
chip with immobilized calumenin was exposed to a £ow with
pure commercial SAP in a bu¡ered solution. In order to con-
¢rm that calumenin in fact interacted with SAP, the presence
of SAP complexing with calumenin was demonstrated by add-
ing an anti-SAP antibody. A prompt increase in response
(curve 1) was seen when the sensor chip with calumenin-
SAP complexes was exposed to a £ow with anti-SAP re£ecting
the association phase of anti-SAP with the calumenin-SAP
complex. Curve 2 demonstrates that the anti-SAP antibody
did not react with immobilized calumenin alone. Fig. 3A rep-
resents one among several experiments. Occasionally, binding
of SAP in bu¡ered solution fails or is unstable. This could be
due to the fact that SAP binds several proteins in a Ca2-
dependent way [23^26] that might stabilize the interaction. In
order to circumvent these problems we chose to perform the
experiments in a serum-like medium. We therefore gelfractio-
nated human serum.
About 200 fractions were analyzed for the presence of SAP
by Western blotting with anti-SAP antibody (Fig. 3B). SAP
enriched fractions (pooled fractions 72^76) and SAP depleted
fractions (pooled fractions 88^92) were subsequently analyzed
for calumenin binding activity. In Fig. 3C a prompt increase
in response was seen when the sensor chip with immobilized
calumenin was exposed to a £ow with SAP enriched serum
fractions diluted 1 to 20 times (curves 1^7) re£ecting the asso-
ciation phase of the calumenin-SAP interaction. The bound
SAP dissociated slowly as detected by a slow decrease in the
response by injecting bu¡er alone. The dissociation phase
(Fig. 3C) is apparently not monophasic but bi- or multiphasic
suggesting molecular heterogeneity of the SAP-calumenin
complexes formed. The self aggregation of SAP and of cal-
umenin and the presence of other components in serum that
may participate in the complex formation may all take part in
the dissociation phase. However, further dissection of the mo-
lecular nature of the heterogeneous complexes must await
more detailed studies. The speci¢city and the Ca2-depend-
ence of the SAP-calumenin interaction were veri¢ed by mon-
itoring Ca2-depleted samples. Curve 8 shows that the bind-
ing is abolished when 3.4 mM EDTA was added to the
sample with the highest SAP content.
In Fig. 3D (curve 2) an increase in response was seen when
the sensor chip was exposed to a £ow with three times diluted
SAP enriched serum fractions (equivalent to curve 3 in Fig.
3C). In order to con¢rm that immobilized calumenin in fact
interacted with SAP, present among several other components
in the SAP enriched serum fractions, the presence of SAP
complexing with calumenin was also here demonstrated by
adding an anti-SAP antibody. A prompt increase in response
(curve 1) was seen when the sensor chip with calumenin-SAP
complexes was exposed to a £ow with anti-SAP re£ecting the
association phase of the anti-SAP antibody with the calume-
nin-SAP complex. Curve 3 demonstrates that the anti-SAP
antibody did not react with immobilized calumenin alone.
Fig. 3E (curve 2) shows binding activity of SAP-depleted
fractions to which commercially available SAP has been
added. The presence of commercial SAP complexing with
the calumenin was again demonstrated by adding anti-SAP
(curve 1). Curve 3 shows absence of binding activity of
SAP-depleted fractions with no addition of commercial
SAP. The apparent horizontal curve seen after the wash
(Fig. 3E, curve 2) re£ects a low dissociation constant and
thereby a strong a⁄nity of SAP to the column as previously
Fig. 4. Surface plasmon resonance analysis of the in£uence of Ca2
on the interaction of SAP with calumenin. In each cycle commercial
SAP (50 nM) in SAP depleated serum fractions (#88^92) was in-
jected onto the calumenin chip in 10 mM HEPES, 150 mM NaCl,
5 mM CaCl2, 1 mM EGTA, pH 7.4. Next, a bu¡er (10 mM
HEPES, 150 mM NaCl, 1 mM EGTA, pH 7.4) containing decreas-
ing amounts of free Ca2 as given was injected in the dissociation
phase. The initial dissociation rate constants were determined as
8.8U1035 s31, 8.7U1035 s31, 76.1U1035 s31, 516U1035 s31,
1820U1035 s31, and 1031 s31, respectively.
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concluded (Fig. 2B). However, the interaction is still reversible
as seen by the release of SAP by EDTA in bu¡er (Fig. 2B) as
well as in the serum-like medium (Fig. 3C). It should be noted
that there may be di¡erences in the binding strength of the
pure SAP in bu¡ered solution and the SAP in serum, since the
latter may contain complexes of SAP with other ligands
present in serum known to bind to SAP.
Fig. 4 shows a quantitative assessment of the Ca2 depend-
ence of the SAP-calumenin interaction. The association phase
was performed in presence of 4 mM free Ca2. The Ca2
concentration in the dissociation phase was varied stepwise
between 0 and 5 mM. At a free Ca2 concentration of 4 or
5 mM (Fig. 4) we found a low dissociation constant at
9U1035 s31 corresponding to a strong a⁄nity of SAP to
calumenin. As the Ca2 concentration decreases we ¢nd a
corresponding increasing dissociation rate, i.e. 76U1035 s31
at 3 mM, 516U1035 s31 at 2 mM, 1820U1035 s31 at 1 mM
and 1031 s31 at 0 mM free Ca2 concentration. We thus ¢nd
a marked change in a⁄nity between SAP and calumenin by
changing the free Ca2 concentration in the mM range.
In conclusion, the surface plasmon resonance analysis
clearly veri¢es and demonstrates a Ca2-dependent interaction
between calumenin and SAP in the mM range of free Ca2.
4. Discussion
Calumenin belongs to a subset of the EF-hand superfamily
in the ER and Golgi apparatus consisting of reticulocalbin
[11], ERC-55 [12], Cab45 [27], crocalbin [15] and calumenin
[14,28]. Due to structural similarities among the members of
this family they are likely to share some functional properties.
However, marked di¡erences also exist between them. Espe-
cially, calumenin is distinct from the others. Intracellularly, it
localizes to the whole secretory pathway whereas reticulocal-
bin and ERC-55 both are localized to the ER, and Cab45 is
exclusively found in the Golgi compartment. Furthermore,
calumenin is the ¢rst member of this family reported to be
secreted [20].
In order to further investigate the function of calumenin we
immobilized the recombinant calumenin to a column. After
application of a placental tissue extract and after washing
with a high concentration of salt we were able to elute one
protein that interacts with calumenin in the presence of Ca2.
Sequencing of a tryptic internal peptide identi¢ed this protein
as SAP. SAP, which is mainly synthesized in the liver and
secreted to the blood stream, belongs to the pentraxin family
of plasma proteins and serves a function in non-speci¢c im-
munity [29]. It is a glycoprotein composed of 10 identical,
non-covalently linked 25-kDa subunits, which are arranged
in two parallel cyclic pentagonal structures interacting face-
to-face [30]. Each subunit may bind two Ca2-ions and this
complex may bind several ligands including DNA and chro-
matin, ¢bronectin, complement component 4-binding protein,
glycosaminoglycans, heparan and phosphorylethanolamine
[23^26]. All these interactions are Ca2-dependent and appear
to involve a unique binding site in the SAP molecule [31,32].
SAP is related in structure to C-reactive protein (CRP),
which also belongs to the pentraxin protein family [33,34].
In humans CRP is a major acute phase reactant that is mas-
sively induced by in£ammation and provides enhanced pro-
tection against invading micro-organisms, limit tissue damage
and promote a rapid return to homeostasis [29]. Although
SAP is not a major acute phase reactant in humans it may
still be induced locally or systemically by di¡erent combina-
tions of cytokines [29]. Calumenin, with its ubiquitous pres-
ence [14], might thus in some way participate in this host
defence system.
Although the physiological function of SAP is largely un-
known, SAP has received considerable medical interest as it
associates with all types of amyloid deposits, including those
found in Alzheimer’s disease [33,35]. SAP has a high tendency
to undergo Ca2-dependent self-aggregation, which may be
important for its deposition in amyloid. Interestingly, our
study shows that calumenin also in solution forms high mo-
lecular mass aggregates with about 10 or more molecules.
Thus, the tendency of both molecules to form high molecular
mass aggregates together with the fact that they bind each
other in the presence of Ca2 might play a role in the patho-
genesis of amyloidosis.
We have previously determined that each of the EF-hands
of calumenin binds the Ca2 ion with a dissociation constant
of 0.6 mM [14]. The free Ca2 concentration extracellularly is
in the mM range but also intracellularly in the ER the free
Ca2 concentration may vary up to the 3^5 mM area [36]. The
Ca2 dissociation constants of the calumenin EF-hands are
thus close to the level of the free Ca2 concentration where
calumenin is localized, i.e. in the secretory pathway and ex-
tracellularly suggesting that the EF-hands of calumenin may
well serve a regulatory role rather than a structural role.
In summary, we were able to identify SAP as the ¢rst ligand
known to interact with calumenin. The calumenin-SAP inter-
action was veri¢ed and characterized by the surface plasmon
resonance technique. The ¢ndings may indicate that calume-
nin could participate in the immunological defense system and
be involved in the pathological process of amyloidosis that
leads to formation of amyloid deposits.
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